iRhythm Technologies Dirección

Dirección controles de criterios 2/4

El CEO de iRhythm Technologies es Quentin Blackford , nombrado en Oct 2021, tiene una permanencia de 3.08 años. compensación anual total es $16.60M, compuesta por 4.1% salario y 95.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.26% de las acciones de la empresa, por valor de €6.26M. La antigüedad media del equipo directivo y de la junta directiva es de 2.5 años y 7.3 años, respectivamente.

Información clave

Quentin Blackford

Chief Executive Officer (CEO)

US$16.6m

Compensación total

Porcentaje del salario del CEO	4.1%
Permanencia del CEO	3.1yrs
Participación del CEO	0.3%
Permanencia media de la dirección	2.5yrs
Promedio de permanencia en la Junta Directiva	7.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Quentin Blackford en comparación con los beneficios de iRhythm Technologies?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$151m
Jun 30 2024	n/a	n/a	-US$132m
Mar 31 2024	n/a	n/a	-US$130m
Dec 31 2023	US$17m	US$677k	-US$123m
Sep 30 2023	n/a	n/a	-US$105m
Jun 30 2023	n/a	n/a	-US$99m
Mar 31 2023	n/a	n/a	-US$105m
Dec 31 2022	US$8m	US$650k	-US$116m
Sep 30 2022	n/a	n/a	-US$128m
Jun 30 2022	n/a	n/a	-US$131m
Mar 31 2022	n/a	n/a	-US$124m
Dec 31 2021	US$10m	US$163k	-US$101m

Compensación vs. Mercado: La compensación total de Quentin($USD16.60M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.95M).

Compensación vs. Ingresos: La compensación de Quentin ha aumentado mientras la empresa no es rentable.

CEO

Quentin Blackford (45 yo)

3.1yrs

Permanencia

US$16,595,149

Compensación

Mr. Quentin S. Blackford serves as an Independent Director of Paragon 28, Inc. since August 1, 2022. He serves as President and Chief Executive Officer since October 04, 2021 and serves as Director at iRhy...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Quentin Blackford	President	3.1yrs	US$16.60m	0.26% € 6.3m
Minang Turakhia	Chief Medical & Scientific Officer and Executive VP of Product Innovation	2.6yrs	US$5.32m	0.015% € 370.5k
Patrick Murphy	Chief Business & Legal Officer	2.9yrs	US$5.33m	0.031% € 730.0k
Chad Patterson	Chief Commercial Officer	2.3yrs	US$5.77m	0.025% € 600.8k
Mervin Smith	Executive Vice President of Business Operations	1.3yrs	sin datos	0.0023% € 56.0k
Marc Rosenbaum	Senior VP of Finance & Chief Accounting Officer	1.3yrs	sin datos	0.0029% € 69.4k
Daniel Wilson	Executive VP of Corporate Development & Investor Relations	5.4yrs	US$3.54m	0.098% € 2.3m
Sumi Shrishrimal	Executive VP & Chief Risk Officer	2.5yrs	sin datos	0.074% € 1.8m
Stephanie Zhadkevich	Director of Investor Relations	no data	sin datos	sin datos

2.5yrs

Permanencia media

45yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de I25 se considera experimentado (2.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Quentin Blackford	President	2.8yrs	US$16.60m	0.26% € 6.3m
Ralph Snyderman	Independent Director	7.3yrs	US$233.12k	0.032% € 771.1k
Michael Mirro	Medical Director & Member of Scientific Advisory Board	no data	sin datos	sin datos
Bruce Bodaken	Independent Director	7.3yrs	US$240.25k	0.030% € 721.4k
Abhijit Talwalkar	Independent Chairman	8.5yrs	US$286.74k	0.055% € 1.3m
R. Mead	Medical Director & Member of Scientific Advisory Board	no data	sin datos	sin datos
James Quinn	Member of Scientific Advisory Board	no data	sin datos	sin datos
Cathleen Noel Merz	Independent Director	6.6yrs	US$230.62k	0.018% € 441.3k
Mark Rubash	Independent Director	8.7yrs	US$248.12k	0.034% € 809.1k
Mehdi Razavi	Medical Director & Member of Scientific Advisory Board	no data	sin datos	sin datos
Karen Ling	Independent Director	3yrs	US$239.97k	0.020% € 486.7k
Jay Alexander	Medical Director & Member of Scientific Advisory Board	no data	sin datos	sin datos

7.3yrs

Permanencia media

67yo

Promedio de edad

Junta con experiencia: La junta directiva de I25 se considera experimentada (7.3 años de antigüedad promedio).

iRhythm Technologies Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

President recently sold €1.1m worth of stock

iRhythm Technologies, Inc., Annual General Meeting, May 29, 2024

President recently sold €2.8m worth of stock

Insider recently sold €680k worth of stock

Executive VP & Chief Risk Officer recently sold €115k worth of stock

iRhythm Technologies, Inc. Announces Director Appointments

Recent updates

President recently sold €1.1m worth of stock

Third quarter 2024 earnings released: US$1.48 loss per share (vs US$0.89 loss in 3Q 2023)

iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device

iRhythm Technologies, Inc. to Report Q3, 2024 Results on Oct 30, 2024

New minor risk - Profitability

iRhythm Technologies, Inc. Reaffirms Earnings Guidance for the Year 2024

iRhythm Technologies, Inc. Announces Results of GUARD-AF Trial

New minor risk - Share price stability

Second quarter 2024 earnings released: US$0.65 loss per share (vs US$0.61 loss in 2Q 2023)

Irhythm Technologies, Inc. Provides Earnings Guidance for the Year 2024

iRhythm Technologies, Inc. to Report Q2, 2024 Results on Aug 01, 2024

iRhythm Technologies, Inc. Achieves Significant Operational Milestone with Launch of Initial Phase of Manufacturing Automation

Forecast to breakeven in 2026

iRhythm Technologies, Inc. Revises Earnings Guidance for the Year 2024

iRhythm Technologies, Inc. to Report Q1, 2024 Results on May 02, 2024

New minor risk - Profitability

iRhythm Technologies, Inc., Annual General Meeting, May 29, 2024

New minor risk - Shareholder dilution

President recently sold €2.8m worth of stock

Forecast to breakeven in 2026

Full year 2023 earnings released: US$4.04 loss per share (vs US$3.88 loss in FY 2022)

iRhythm Technologies, Inc. Provides Earnings Guidance for the Year 2024

iRhythm Technologies, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against iRhythm Technologies, Inc

iRhythm Technologies, Inc. Revises Revenue Guidance for the Year 2024

Insider recently sold €680k worth of stock

iRhythm , Inc. Announces Results from the Cardiac Ambulatory Monitor EvaLuation of Outcomes and Time to Events

iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.89 loss per share (vs US$0.71 loss in 3Q 2022)

iRhythm Technologies, Inc. to Report Q3, 2023 Results on Nov 02, 2023

iRhythm Launches Next Generation Zio Monitor and Enhanced Zio Service: Its Smallest, Lightest and Thinnest Cardiac Monitor

Second quarter 2023 earnings released: US$0.61 loss per share (vs US$0.80 loss in 2Q 2022)

iRhythm Technologies, Inc. Provides Earnings Guidance for the Full Year 2023

iRhythm Technologies, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Executive VP & Chief Risk Officer recently sold €115k worth of stock

iRhythm Technologies, Inc. Announces Director Appointments

iRhythm Technologies, Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$1.29 loss per share (vs US$1.71 loss in 1Q 2022)

Now 23% undervalued

COO & Secretary recently sold €391k worth of stock

Full year 2022 earnings released: US$3.88 loss per share (vs US$3.46 loss in FY 2021)

iRhythm Technologies, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Chief Legal Counsel recently sold €174k worth of stock

President recently sold €1.6m worth of stock

Now 20% undervalued after recent price drop

Third quarter 2022 earnings released: US$0.71 loss per share (vs US$0.81 loss in 3Q 2021)

iRhythm Technologies, Inc. Revises Earnings Guidance for the Year 2022

iRhythm Technologies, Inc. to Report Q3, 2022 Results on Nov 01, 2022

iRhythm Technologies, Inc. Reiterates Revenue Guidance for the Year 2022

iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year of 2022

Second quarter 2022 earnings released: US$0.80 loss per share (vs US$0.59 loss in 2Q 2021)

iRhythm Technologies, Inc. Appoints Brice Bobzien as Chief Financial Officer, Effective August 8, 2022

iRhythm Gains FDA Clearance for its Clinically Integrated ZEUS System

iRhythm Technologies, Inc. Announces Management Changes

Executive Vice President of Strategy recently sold €152k worth of stock

Independent Director recently sold €54k worth of stock

First quarter 2022 earnings released: US$1.71 loss per share (vs US$0.95 loss in 1Q 2021)

iRhythm Technologies, Inc. Provides Earnings Guidance for the Fiscal Year 2022

iRhythm Technologies, Inc. to Report Q1, 2022 Results on May 05, 2022

iRhythm Technologies, Inc., Annual General Meeting, May 26, 2022

iRhythm Technologies, Inc. Announces the Results of Three Clinical Research Studies Presented At the American College of Cardiology’s 71 Annual Scientific Session & Expo

Consultant & Director recently sold €828k worth of stock

iRhythm Technologies, Inc. Announces the Results of the KP-Rhythm2 Study

iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

COO, CFO & Secretary recently sold €490k worth of stock

iRhythm Technologies, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Insufficient new directors

Third quarter 2021 earnings released: US$0.81 loss per share (vs US$0.17 loss in 3Q 2020)